


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

| OMB APPROVAL |
|--------------------------------------------------|
| OMB Number: 3235-0076 |
| Expires: August 31, 2015 |
| Estimated Average burden hours per response: 4.0 |

| 1. Issuer's Identity | | |
|-----------------------------------------------|-----------------------|-----------------------------|
| CIK (Filer ID Number) | Previous Name(s) None | Entity Type |
| 0001553643 | Camp Nine, Inc. | • Corporation |
| Name of Issuer | CAMP NINE, INC. | C Limited Partnership |
| RELMADA THERAPEUTICS, INC. | | C Limited Liability Company |
| Jurisdiction of Incorporation/Organization | • | C General Partnership |
| NEVADA | | C Business Trust |
| Year of Incorporation/Organization | o n | C Other |
| ⋄ Over Five Years Ago | | |
| C Within Last Five Years (Specify Year) | | |
| C Yet to Be Formed | | |
| | | |
| | | |
| | | |





| Relationship: | П | Execut | ive Officer | V | Director | | Promoter | |
|---------------------------|----------|------------|-----------------|-----------|------------------|---------|----------|---|
| Clarification of Response | e (if Ne | ecessarv |) | | | | | |
| Chairman of the Board | | | <u></u> | | | | | |
| | | | | | | | | |
| | | | | | | | | _ |
| Last Name | | | First Name | | | Middle | Name | |
| Kelly | | | Paul | | | | | |
| Street Address 1 | | | | 6 | Street Address 2 | 7 | | |
| 880 Third Avenue | | | | | 12th Floor | | | |
| City | | | State/Province/ | ا Coun | trv | ZIP/Pos | tal Code | |
| New York | | | NEW YORK | | | 10022 | | |
| I TOTAL | | | 1,2,, 10111 | | | 10022 | | |
| Relationship: | П | Execut | ive Officer | V | Director | | Promoter | |
| Clarification of Response | (if No | cessarv | ·) | | | | | |
| or response | (22 2 11 | , cessur y | , | | | | | |
| | | | | | | | | _ |
| Last Name | | | First Name | | | Middle | Name | |
| Shenouda | | | Maged | | |] | | |
| Street Address 1 | | | | | Street Address 2 | Ц | | |
| 880 Third Avenue | | | | [| 12th Floor | | | |
| City | | | State/Province/ | Coun | | 7IP/Pos | tal Code | |
| New York | | | NEW YORK | | | 10022 | | |
| Liter Total | | | 1,2,, 10111 | | | 10022 | | |
| Relationship: | П | Execut | ive Officer | V | Director | | Promoter | |
| Clarification of Response | (if Ne | ecessarv | 7) | | | | | |
| | | | , | | | | | |
| | | | | | | | | _ |
| Last Name | | | First Name | | | Middle | Name | |
| Vitolo | | | Ottavio | | | 1 | | |
| Street Address 1 | | | | | Street Address 2 | П | | |
| 880 Third Avenue | | | | [| 12th Floor | | | |
| City | | | State/Province/ | Coun | | ZIP/Pos | tal Code | |
| New York | | | NEW YORK | Coun | | 10022 | tai Couc | |
| THEW TOTAL | | | NEW TORK | | | 10022 | | |
| Relationship: | V | Exposit | ive Officer | _ | Director | | Promoter | |
| Relationship: | 12 | EACCUI | ive Officer | | | | Promoter | |
| Clarification of Response | (if No | ecessary | ·) | | | | | |
| Chief Medical Officer | | | | | | | | |
| | | | | | | | | |

4. Industry Group

| ~ A | griculture | Hea | lth Care | \circ | Retailing |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------|
| | anking & Financial Services | 7000 | Biotechnology | | |
| | Commercial Banking | 0 | Health Insurance Hospitals & Physicians | O | Restaurants |
| 200 | Insurance | 0 | Pharmaceuticals | | Technology |
| Č | Investing | O | Other Health Care | | Computers |
| (| Investment Banking | | | | C Telecommunications |
| (| Pooled Investment Fund | | | | C Other Technology |
| (| Other Banking & Financial Services | | | | Travel |
| C p. | usiness Services | Mar | nufacturing | | C Airlines & Airports |
| | nergy | Real | l Estate Commercial | | C Lodging & Conventions |
| | Coal Mining | 0 | Construction | | C Tourism & Travel Services |
| | Electric Utilities | O | REITS & Finance | 200 | C Other Travel |
| | Energy Conservation | C | Residential | 0 | Other |
| | Environmental Services Oil & Gas | C | Other Real Estate | | |
| | Other Energy | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| 5. I | ssuer Size | | | | |
| Reven | ue Range | | Aggregate Net Asset | Valu | ue Range |
| • | No Revenues | | C No Aggregat | e Ne | et Asset Value |
| C | \$1 - \$1,000,000 | | C \$1 - \$5,000,0 | 00 | |
| C | \$1,000,001 - \$5,000,000 | | C \$5,000,001 - | \$25, | 000,000 |
| C | \$5,000,001 - \$25,000,000 | | C \$25,000,001 | - \$50 | 0,000,000 |
| 0 | \$25,000,001 - \$100,000,000 | | C \$50,000,001 | - \$10 | 00,000,000 |
| | | | | 00.00 | |
| С | Over \$100,000,000 | | Over \$100,00 | 00,00 | 00 |
| 0 | Over \$100,000,000 Decline to Disclose | | C Decline to Di | | |
| 7020 | | | 1. 1 | isclo | |
| C | Decline to Disclose | | C Decline to Di | isclo | |
| 0 | Decline to Disclose Not Applicable | nd | C Decline to Di | isclo ble | se |
| 0 | Decline to Disclose Not Applicable Federal Exemption(s) and | nd | C Decline to Di | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) | | C Decline to Di C Not Applicat Exclusion(s) Clain | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and a column should be seen to | | C Decline to Di C Not Applicat Exclusion(s) Clain | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dity) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) | | C Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) | | C Decline to Di C Not Applicat Exclusion(s) Clain | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dity) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) | | C Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) | isclo ble | se |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) | me | d (select all that |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) | | C Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) | me | d (select all that |
| 6. F | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) | | C Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) | | C Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) | me | d (select all that |
| 6. Fapp | Decline to Disclose Not Applicable Federal Exemption(s) alphy Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iiii) | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all oly) Rule 504(b)(1) (not (i), (ii) or (ii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iiii) Type of Filing New Notice Date of First Sale | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all oly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all oly) Rule 504(b)(1) (not (i), (ii) or (ii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iiii) Type of Filing New Notice Date of First Sale | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all oly) Rule 504(b)(1) (not (i), (ii) or (ii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iiii) Type of Filing New Notice Date of First Sale | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all obly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Fype of Filing New Notice Date of First Sale Amendment | | C Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | me | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Pype of Filing New Notice Date of First Sale Amendment Duration of Offering | 20 | Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | ne | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) all obly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Fype of Filing New Notice Date of First Sale Amendment | 20 | Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | ne | d (select all that |
| 6. F app | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Pype of Filing New Notice Date of First Sale Amendment Duration of Offering | 20 | Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | ne | d (select all that |
| 6. Fapp | Decline to Disclose Not Applicable Federal Exemption(s) and Dly) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Pype of Filing New Notice Date of First Sale Amendment Duration of Offering | 200 | Decline to Di C Not Applicat Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec | ne | d (select all that |
| 6. Fapp | Decline to Disclose Not Applicable Federal Exemption(s) alphy Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Pype of Filing New Notice Date of First Sale Amendment Duration of Offering the Issuer intend this offering to last more properties of Securities Offering Type(s) of Securities Offering | 200 | Decline to Di C Not Applicate Exclusion(s) Clain Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Securities 19-06-14 | ne | d (select all that |

| | tion, Warrant or Other Right to quire Another Security | |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------|
| Security to be Acquired Upon | | |
| Exercise of Option, Warrant or Other Right to Acquire Security | her (describe) | |
| | | |
| | | |
| 10. Business Combination | Transaction | |
| Is this offering being made in connection with transaction, such as a merger, acquisition or e | | No |
| Clarification of Response (if Necessary) | | |
| | | |
| | | |
| 11. Minimum Investment | | |
| Minimum investment accepted from any outsi investor | de \$ 10000 | USD |
| | | |
| 12. Sales Compensation | | |
| Recipient | Recipient CRD Number | None |
| Alexander Capital, LP | 40077 | |
| (Associated) Broker or Dealer | None (Associated) Broker or Deale Number | r CRD None |
| | | |
| Street Address 1 | Street Address 2 | |
| 17 STATE STREET | 5TH FLOOR | |
| City | State/Province/Country | ZIP/Postal Code |
| NEW YORK | NEW YORK | 10004 |
| State(s) of Solicitation | Foreign/Non-US | |
| AL ADAMA | | |
| ARIZONA | | |
| COLORADO | | |
| CONNECTICUT | | |
| FLORIDA | | |
| GEORGIA | | |
| ILLINOIS | | |
| INDIANA | | |
| KENTUCKY | | |
| MARYLAND | | |
| MASSACHUSETTS | | |
| MINNESOTA NEW JEDSEY | | |
| NEW YORK | | |
| OREGON OREGON | | |
| RHODE ISLAND | | |
| SOUTH CAROLINA | | |
| TEXAS | | |
| | | |
| Recipient | Recipient CRD Number | None |
| Brookline Capital Markets, A division o Securities, LLC | f Arcadia 44656 | |
| (Associated) Broker or Dealer | None (Associated) Broker or Deale Number | r CRD None |
| | | |

| Street Address 1 | | | Street Address 2 | | |
|----------------------------|-------------------------------------------------------------------|----------|--------------------------|---------|-----------------|
| 509 MADISON AVI | ENUE, SUITE 906 | | | | |
| City | | State/ | Province/Country | | ZIP/Postal Code |
| NEW YORK | | NEV | V YORK | | 10022 |
| State(s) of Solicitation | ☐ All States ☐ | Fore | ign/Non-US | | |
| | L | | -8 | | |
| ALASKA | | | | | |
| ARIZONA | | | | | |
| COLORADO | | | | | |
| GEORGIA | | | | | |
| MARYLAND | | | | | |
| MICHIGAN | | | | | |
| MISSISSIPPI | | | | | |
| NEW JERSEY | | | | | |
| NEW YORK | | | | | |
| NORTH CAROLINA | | | | | |
| ОНЮ | | | | | |
| TEXAS | | | | | |
| WYOMING | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| 13 Offering a | nd Sales Amount | to | | | |
| 13. Offering a | ilu Sales Amouni | เอ | | | |
| Total Offering Amount | \$ 10000000 | USI | ☐ Indefinite | | |
| _ | | # | | | |
| Total Amount Sold | \$ 8002248 | USI | , | | |
| Total Remaining to be Sold | \$ 1997752 | USI | ☐ Indefinite | | |
| Clarification of Respons | a (if Nacassary) | | | | |
| Claimeation of Respons | c (ii ivecessai y) | | | | |
| | | | | | |
| 14. Investors | | | | | |
| 14. 1117031013 | | | | | |
| | | | | | |
| do not qualify | ities in the offering have been as accredited investors, | n or ma | y be sold to persons wh | 0 | |
| | ch non-accredited investors v | who alr | eady have invested in th | ne | |
| | whathay sacquifies in the off | ovina ha | vo boon on mov be cold | | |
| to persons who | whether securities in the offer o do not qualify as accredited | d invest | ors, enter the total | 108 | |
| number of inv | estors who already have inve | ested in | the othering: | | |
| - | | | | | |
| 15. Sales Con | nmissions & Find | lers' | Fees Expense | es | |
| | amounts of sales commissions rn, provide an estimate and c | | | | mount of an |
| - | Commissions \$ 831370 | | USD | ☐ Estir | nate |
| | | | | * | |
| F | 'inders' Fees \$ 0 | | USD | Estir | пате |
| Clarification of Respons | se (if Necessary) | | | | |
| | nd Brookline received a car rrants to purchase an aggr | | | | |

| Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to |
|-------------------------------------------------------------------------------------------------------------------|
| any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above |
| If the amount is unknown, provide an estimate and check the box next to the amount. |

| | 1 | |
|---------|-----|----------|
| \$ 0 | USD | Estimate |

Clarification of Response (if Necessary)

In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 affirmed.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer | Signature | Name of Signer | Title | Date |
|----------------------------------|---------------------|-----------------|-------|------------|
| RELMADA THERAPEUTICS, INC. | /s/ Sergio Traversa | Sergio Traversa | СЕО | 2019-06-27 |